https://pharmadevicenews.com/how-verismos-multi-chain-kir-car-platform-differs-from-conventional-car-t/ PharmaDeviceNews en 2026-11-06T13:15:09+00:00 How Verismo’s multi-chain KIR-CAR platform differs from conventional CAR-T American Society of Hematology, Brian Kim, CELESTIAL-301, Colorado Blood Cancer Institute, HLB Innovation, Michael Tees, SynKIR-310, Verismo Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/01/lymphoma-research.webp https://pharmadevicenews.com/emergent-biosolutions-wins-22-3m-biothrax-order-as-us-military-maintains-anthrax-preparedness/ PharmaDeviceNews en 2026-11-06T13:10:25+00:00 Emergent BioSolutions wins $22.3m BioThrax order as US military maintains anthrax preparedness Biomedical Advanced Research and Development Authority, BioThrax, CYFENDUS, Defense Health Agency, Emergent BioSolutions, Joe Papa, Paul Williams, United States Department of War https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/innovivas-antibiotics-are-growing-45-so-why-did-the-company-report-a-73-9m-loss/ PharmaDeviceNews en 2026-11-05T04:16:52+00:00 Innoviva’s antibiotics are growing 45%, so why did the company report a $73.9m loss? Armata Pharmaceuticals, Basilea Pharmaceutica, Entasis Therapeutics, GIAPREZA, GSK, Innoviva Inc., Innoviva Specialty Therapeutics, NUZOLVENCE, Pavel Raifeld, XACDURO, XERAVA, ZEVTERA https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/summit-therapeutics-has-2bn-from-astrazeneca-and-stronger-cancer-survival-data-but-will-the-fda-approve-ivonescimab/ PharmaDeviceNews en 2026-11-05T04:12:47+00:00 Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab? Akeso, AstraZeneca, Daiichi Sankyo, Datroway, HARMONi, HARMONi-2, HARMONi-3, HARMONi-7, Ivonescimab, Maky Zanganeh, Robert W. Duggan, Summit Therapeutics Inc. https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/evommune-bets-30m-on-a-vav1-degrader-that-could-challenge-jak-inhibitors-but-can-it-deliver-safer-autoimmune-treatment/ PharmaDeviceNews en 2026-11-05T04:08:47+00:00 Evommune bets $30m on a VAV1 degrader that could challenge JAK inhibitors, but can it deliver safer autoimmune treatment? EVO301, EVO570, EVO756, Evommune Inc., Greg Moss, HC118, Hinova Pharmaceuticals, Jeegar Patel, Yuanwei Chen https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/iadademstat-shows-95-response-rate-in-leukemia-as-oryzon-genomics-prepares-phase-3-development/ PharmaDeviceNews en 2026-11-04T22:01:01+00:00 Iadademstat shows 95% response rate in leukemia as Oryzon Genomics prepares Phase 3 development ALICE-2, ALICE-3, American Society of Hematology, FRIDA, iadademstat, Oryzon Genomics, U.S. National Cancer Institute https://pharmadevicenews.com/wp-content/uploads/2026/11/Leukemia-treatment-research-e1793829387870.webp https://pharmadevicenews.com/fda-grants-breakthrough-designation-to-daridorexant-following-50-minute-sleep-improvement-in-children/ PharmaDeviceNews en 2026-11-04T19:02:30+00:00 FDA grants breakthrough designation to daridorexant following 50-minute sleep improvement in children Daridorexant, Idorsia, QUVIVIQ, Strasbourg University Hospitals, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Pediatric-sleep-research-e1793818125309.webp https://pharmadevicenews.com/pelareorep-shows-promising-hpv-targeted-immune-activity-as-oncolytics-biotech-advances-cancer-research/ PharmaDeviceNews en 2026-11-04T18:42:34+00:00 Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research GOBLET, Oncolytics Biotech, pelareorep, Society for Immunotherapy of Cancer, U.S. Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/11/Cancer-immunotherapy-research-2-e1793817406414.webp https://pharmadevicenews.com/annamycin-leukemia-trial-progresses-toward-pivotal-dose-selection-after-encouraging-interim-results/ PharmaDeviceNews en 2026-11-04T18:10:00+00:00 Annamycin leukemia trial progresses toward pivotal dose selection after encouraging interim results American Society of Hematology, annamycin, Arensia Exploratory Medicine, MIRACLE trial, Moleculin Biotech, naxtarubicin https://pharmadevicenews.com/wp-content/uploads/2026/11/Myeloid-leukemia-research-e1793815690864.webp